Global Biopharma Company Continues to Invest in Ireland

Alkermes will invest €20m over the next three years to modernise its manufacturing facility based in Athlone.

Alkermes is a global biopharmaceutical company developing innovative medicines for the treatment of the central nervous system (CNS) diseases.

The company employs more than 400 people in Ireland at its manufacturing and drug development facility in Athlone, Co. Westmeath and at its global headquarters operation in Dublin, with more than 1,200 employees worldwide.

Alkermes investment will modernise the existing plant to allow the company to focus primarily on the manufacture of new advanced product lines and position the facility for future growth.

Richard Pops, Chief Executive Officer of Alkermes plc, said: “Ireland has established a solid track record as the ideal location for many of the world’s leading pharmaceutical businesses. We see our Irish base as important to the evolution of our business, both in our European markets and globally”.

As part of the refurbishment Dortek have recently installed more than 93 hygienic doors and 42 observation windows at the site. The range of doors included hygienic hinged and sliding doors, automated doors, fire rated doors, rapid roll doors, transfer hatches and observation windows. Our doors unique seamless design and ledge free windows are critical to meeting strict quality standards.

GRP pharmaceutical doorshygienic windows

Designing & Delivering The First Proton Beam Therapy Centre In The UK

The RIAI held its series of Walks +Talks in London at RIBA last week for a talk on design innovation.

As part of the series Scott Tallon Walker architects gave a talk on designing and delivering the first Proton Beam Therapy centre in the UK. The £250 million cancer hospital and proton beam therapy (PBT) centre in London will be the first facility of its kind in the UK and one of just a handful in the world.

Speaking at the event, RIAI President Robin Mandal said: “Scott Tallon Walker have long been a central part of the practice of architecture in Ireland. One of the earliest firms to internationalise, it is remarkable that they are designing the first proton beam therapy unit in London. The ionization that directed proton beam radiation causes to cell atoms is a great hope for cancer patients and a huge advance in radiation therapy. As with all architecture, this architecture is the hallmark of a civil society at a stage of its development. This project also shows the interconnection of the three strands that make all great projects: collaboration, looking outwards and valuing cultural identity.”

About Walks + Talks
The Walks + Talks series was originally devised by the RIAI to engage the public with award-winning buildings, illustrated through building tours and conversations with the architects. RIAI Walks + Talks London forms part of the RIAI’S official programme for the year of Irish Design, ID2015 – a year-long initiative backed by the Irish government promoting and celebrating Irish design.

Pictured above from LR – Robin Mandal (President of RIAI), Angela Brady (Director of Brady Mallalieu Architects, Douglas Hill (Regional Manager, Dortek), Paul Coley (Specification Manager, Dortek).

Read more about the event here –http://www.riai.ie/news/article/id2015_riai_walks_talks_with_scott_tallon_walker_london

DSC_1596DSC_1638

 

Back To Top